Oncology
 |
|
20 february 2019 01:04:14 |
| A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine (British Journal of Cancer) |
|
Tweet |
| 38 viewsCategory: Oncology |
 Microbiota and immune cell interplay (Nature Reviews Cancer)Apelin and apelin receptor expression in renal cell carcinoma (British Journal of Cancer) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
